SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Covalent Group Inc (CVGR) an undiscovered CRO -- Ignore unavailable to you. Want to Upgrade?


To: Gurupup who wrote (52)5/14/1998 8:44:00 PM
From: JanyBlueEyes  Read Replies (1) | Respond to of 107
 
WAYNE, Pa., May 14 /PRNewswire/ -- Covalent Group, Inc. (NASDAQ:CVGR) today announced results for the first quarter of 1998. Covalent reported revenues of $2,240,000 and a net loss of $266,000 or $.02 per share (basic and diluted). These financial results are down in comparison to revenues of $3,046,000 and net income of $99,000 or $.01 per share (basic and diluted) for the first quarter of last year.

Bruce LaMont, President and Chief Executive Officer commented, "First quarter results as compared to last year reflect the impact of conducting one less major clinical study. As mentioned in an announcement earlier this year, we have bolstered our sales efforts and now have bids pending with current and prospective customers for large, multi-year studies. We expect closure on these proposals in the near future and anticipate a very high success rate in securing this business."

Mr. LaMont added, "I believe the first quarter was a low water mark for the Company and expect better performance in the future</b. The business we anticipate winning plus other opportunities, while not fully assuring achievement of our 1998 sales plan, give us confidence we are proceeding in the right direction and building an underlying base of business for the future."

Covalent provides drug development and health management solutions to drug and device manufacturers, as well as to managed care organizations. To aid its pharmaceutical and managed care customers, Covalent has developed an automated data collection system using an interactive voice recognition system -- Virtual HouseCall.

This press release contains forward-looking statements.......